Clinical Trials
150 trialsA Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Pfizer
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Pfizer
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Deciphera Pharmaceuticals, LLC
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
Mayo Clinic
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
Mayo Clinic
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
A Study of ASP1012 in Adults With Solid Tumors
Astellas Pharma Inc
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Ikena Oncology
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Herlev Hospital
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
AM-003
University of Virginia
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
A Study to Investigate LYL845 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
RAPTOR
Turnstone Biologics, Corp.
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Novartis
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
BioNTech SE
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
University of California, San Francisco
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
Nouscom SRL
STARLING
Turnstone Biologics, Corp.
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Mayo Clinic
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
ABM Therapeutics Corporation
Dietary Intervention in Patients with a History of Melanoma
M.D. Anderson Cancer Center
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
ABM Therapeutics Shanghai Company Limited
PANAMA
Karyopharm Therapeutics Inc
LTbR
Pfizer
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Astellas Pharma Inc
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
PDL1x41BB
Inhibrx Biosciences, Inc
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)